1.31
前日終値:
$1.32
開ける:
$1.33
24時間の取引高:
94,576
Relative Volume:
0.81
時価総額:
$34.06M
収益:
$2,000
当期純損益:
$-9.12M
株価収益率:
-3.365
EPS:
-0.3893
ネットキャッシュフロー:
$-3.35M
1週間 パフォーマンス:
+1.55%
1か月 パフォーマンス:
+14.91%
6か月 パフォーマンス:
-42.04%
1年 パフォーマンス:
-33.16%
Abvc Biopharma Inc Stock (ABVC) Company Profile
名前
Abvc Biopharma Inc
セクター
電話
510-668-0881
住所
44370 OLD WARM SPRINGS BLVD., FREMONT
Compare ABVC vs VRTX, REGN, ARGX, ALNY, RVMD
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
|
ABVC
Abvc Biopharma Inc
|
1.31 | 35.10M | 2,000 | -9.12M | -3.35M | -0.3893 |
|
VRTX
Vertex Pharmaceuticals Inc
|
468.42 | 114.63B | 12.34B | 4.34B | 3.71B | 16.87 |
|
REGN
Regeneron Pharmaceuticals Inc
|
618.03 | 63.95B | 14.92B | 4.42B | 3.79B | 41.04 |
|
ARGX
Argen X Se Adr
|
853.40 | 54.58B | 4.16B | 1.29B | 734.26M | 19.58 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
288.18 | 37.13B | 4.29B | 577.22M | 641.34M | 4.2086 |
|
RVMD
Revolution Medicines Inc
|
169.51 | 34.65B | 742.00K | -1.37B | -1.07B | -7.0731 |
Abvc Biopharma Inc (ABVC) 最新ニュース
ABVC BioPharma to Spin Off BioKey Subsidiary via Dividend Distribution to Shareholders - citybuzz -
ABVC BioPharma, Inc. Announces Planned Spin-Off of BioKey (Cayman), Inc. Through Dividend Distribution of BioKey Shares to ABVC Shareholders - TradingView
ABVC Biopharma Inc (ABVC) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
ABVC Biopharma Inc (ABVC) Institutional Confidence - TradingKey
ABVC Biopharma Inc (ABVC) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
ABVC Biopharma Inc (ABVC) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
ABVC Biopharma Inc (ABVC) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
ABVC Biopharma Inc (ABVC) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
ABVC Biopharma Inc (ABVC) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
ABVC Biopharma Inc (ABVC) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
ABVC Biopharma Inc (ABVC) Valuation: PE, PB & Fair Value Analysis - TradingKey
ABVC BioPharma Inc. (ABVC) Surges 7.39% — Testing Key Resistance at $1.34Relative Volume - newsline.com
ABVC Q1 2025 Earnings: Net Loss of -$0.06 Per Share Reflects Pre‑Revenue Development Stage; Stock Declines 9.2% - newsline.com
ABVC BioPharma Inc. (ABVC) Edges Higher as Shares Test Resistance Near $1.41Ichimoku Kumo Break - newsline.com
ABVC BioPharma Inc. (ABVC) Q1 2025 Earnings: Narrowing Losses Amid Clinical ProgressRevenue Recognition Risk - newsline.com
ABVC BioPharma Slips 7.6%: Support at $1.26 in Focus After Volatile SessionSeasonality Effect - newsline.com
12 Health Care Stocks Moving In Thursday's Pre-Market Session - Benzinga
ABVC PE Ratio & Valuation, Is ABVC Overvalued - Intellectia AI
ABVC Q1 2025 Earnings: Pre‑Revenue Biotech Reports Net Loss as Pipeline Development Continues - newsline.com
ABVC BioPharma Inc. (ABVC) Q1 2025 Earnings: Modest Loss Reported Amid Ongoing Clinical Development - The Legal Advocate
ABVC BioPharma Creeps Higher, Testing Resistance at $1.48Bullish Percent Index - The Legal Advocate
ABVC BioPharma Consolidates at $1.39 as Support and Resistance Levels NarrowPCR Divergence - The Legal Advocate
ABVC BioPharma Surges 13%: Key Levels and Potential ScenariosShort Term Trading Ideas - thelegaladvocate.com
ABVC BioPharma Inc. (ABVC) Surges 9.65% in Active Trading as Biotech Investor Sentiment ImprovesMcClellan Summation - The Legal Advocate
ABVC BioPharma Inc. (ABVC) Edges Higher After Recent Pullback, Testing Key Resistance LevelIV Expansion Alert - Newser
ABVC BioPharma Inc. Q1 2025 Earnings: Narrowed Loss Highlights Continued Pipeline ProgressBuyback Announcement Report - The Legal Advocate
ABVC BioPharma Inc. (ABVC) Holds Steady Above Support After Modest GainSocial Flow Trades - Newser
ABVC BioPharma Reports Continued Losses and No Revenue in Q1 2026, Raising Doubts About Financial Stability - Minichart
Why Is ABVC BioPharma, Inc. (ABVC) Stock Up Today? - Meyka
Why Is ABVC BioPharma, Inc. (ABVC) Stock Down Today? - Meyka
ABVC BioPharma, Inc. 1Q 2026: Revenue ($1.55M), Net income ($1.56M), EPS ($0.06) — 10-Q Summary - TradingView
ABVC: Q1 2026 saw a $1.69M net loss, no revenue, and a $4.74M working capital deficit - TradingView
ABVC BioPharma (NASDAQ: ABVC) posts Q1 loss and going concern warning - Stock Titan
ABVC BioPharma Delays Quarterly SEC Filing - TipRanks
ABVC (ABVC) files Form 12b-25: late 10-Q for March 31, 2026 - Stock Titan
TradingKey - TradingKey
How sustainable is BioPharma (ABVC) profit margins? (Institutional Selling) 2026-05-08MACD Signals - newser.com
ABVC BioPharma drops 6.14% after Q1 2025 quarterly earnings post a 0.06 dollar per share loss with no prior analyst estimates.Management Guidance Update - newsline.com
ABVC BioPharma Inc. posts $0.06 EPS loss, no published estimatesGuidance Accuracy Score - newsline.com
BioPharma (ABVC) Stock: Why Industry Position (Pulls Back) 2026-04-15Breakout Signals - Cổng thông tin điện tử tỉnh Lào Cai
ABVC Options Volatility — NASDAQ:ABVC - TradingView
ABVC Options Chain — NASDAQ:ABVC - TradingView
Published on: 2026-04-10 10:41:09 - baoquankhu1.vn
12 Health Care Stocks Moving In Monday's Intraday Session - Benzinga
Is BioPharma (ABVC) Stock Growing Now | Price at $1.33, Up 20.91%Fibonacci Retracement - newsline.com
ABVC Stock News Today | Earnings, Events & Price Alerts - Intellectia AI
12 Health Care Stocks Moving In Monday's After-Market Session - Benzinga
ABVC BioPharma Shareholders Back Board, Equity Plan Changes - TipRanks
ABVC BioPharma shareholders approve director slate and equity plan at annual meeting By Investing.com - Investing.com South Africa
ABVC BioPharma shareholders approve director slate and equity plan at annual meeting - Investing.com
ABVC BioPharma (ABVC) investors re-elect board and approve 2026 plan - stocktitan.net
Abvc Biopharma Inc (ABVC) 財務データ
収益
当期純利益
現金流量
EPS
大文字化:
|
ボリューム (24 時間):